Akebia Therapeutics Inc. announced key corporate updates and its 2026 pipeline outlook. The company reported it is positioned to increase the depth of Vafseo (vadadustat) prescribing entering 2026, with access to approximately 275,000 patients. Akebia expects revenue growth to resume in the first quarter of 2026, driven by increased patient access and anticipated improvements in adherence and compliance. In its rare kidney disease pipeline, Akebia dosed the first patient in a Phase 2 clinical trial of Praliciguat for focal segmental glomerulosclerosis $(FSGS)$ in December 2025 and plans to evaluate the drug in other rare podocytopathies. The company also plans to initiate an open-label Phase 2 rare kidney disease basket trial in the second half of 2026, assessing indications such as IgA Nephropathy (IgAN), Lupus Nephritis (LN), and C3 Glomerulopathy (C3G), with initial data expected in 2027. Additionally, AKB-9090, a HIF-PH inhibitor, is scheduled to enter Phase 1 trials for acute kidney injury associated with cardiac surgery in the first half of 2026. The company remains in a solid financial position and continues to advance its mid-stage pipeline alongside the commercial growth of Vafseo.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Akebia Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9623624-en) on January 12, 2026, and is solely responsible for the information contained therein.